دورية أكاديمية
Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats
العنوان: | Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats |
---|---|
المؤلفون: | Shahinaze A. Fouad, Mahmoud H. Teaima, Mostafa I. Gebril, Fathy I. Abd Allah, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal |
المصدر: | Drug Delivery, Vol 30, Iss 1 (2023) |
بيانات النشر: | Taylor & Francis Group, 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Therapeutics. Pharmacology |
مصطلحات موضوعية: | Diabetes mellitus (type II), repaglinide, niosomes, coprocessed excipients, dysphagia, chewable tablets, Therapeutics. Pharmacology, RM1-950 |
الوصف: | AbstractRepaglinide (RPG), a monotherapy insulin secretagogue used to treat diabetes mellitus-type II yet, it suffers from poor water solubility and variable bioavailability (∼ 50%) due to hepatic first pass metabolism. In this study, 2FI I-Optimal statistical design was employed to encapsulate RPG into niosomal formulations using cholesterol,span 60 and peceolTM. The optimized niosomal formulation (ONF) showed particle size 306.60 ± 84.00 nm, zeta potential −38.60 ± 1.20 mV, polydispersity index 0.48 ± 0.05 and entrapment efficiency 92.00 ± 2.60%. ONF showed > 65% RPG release that lasted for 3.5 h, and significantly higher sustained release compared to Novonorm® tablets after 6 h (p |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 10717544 1521-0464 1071-7544 |
Relation: | https://doaj.org/toc/1071-7544; https://doaj.org/toc/1521-0464 |
DOI: | 10.1080/10717544.2023.2181747 |
URL الوصول: | https://doaj.org/article/3ba05543f1014e0283e9f324dd9f7d65 |
رقم الأكسشن: | edsdoj.3ba05543f1014e0283e9f324dd9f7d65 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 10717544 15210464 |
---|---|
DOI: | 10.1080/10717544.2023.2181747 |